Home  >  News
Eppen_CellXpert_Feb25
Waters_Ebook_Dec24
you can get e-magazine links on WhatsApp. Click here
Biotechnology + Font Resize -

C-CAMP partners with IHMA global microbio lab for development and commercialization of solutions to combat AMR

Our Bureau, Bengaluru
Friday, December 4, 2020, 17:10 Hrs  [IST]

Centre for Cellular and Molecular Platforms (C-CAMP) has signed a Memorandum of Understanding (MoU) with International Health Management Associates (IHMA).

C-CAMP and IHMA will jointly facilitate microbiology-related studies for clinical trials, surveillance studies, mentorship programmes and other activities to promote new drug and vaccine discovery in the area of anti-infectives and new-age diagnostic device development to address AMR.

Now IHMA with its advanced microbiology lab is supporting anti-infective and diagnostic development studies for over 25 years has laboratory facilities in the US, Switzerland and China plus a business office in India. C-CAMP is currently working on solutions against AMR through its AMR Accelerator programme that was launched in 2020.

“AMR is widely acknowledged as the biggest threat to 21st century medicine. As innovators across the world race to develop next generation antimicrobials and vaccines, it is crucial that the regulatory and commercial routes to success for these paths are smooth and obstacle-free. We are delighted to announce that this MoU with IHMA will bring a world-class 360-degree service model to Indian innovators in the drug discovery arena along with exposure to global regulatory standards,” said Dr Taslimarif Saiyed, C-CAMP’s CEO and director.

The Bengaluru-based C-CAMP is positioned as India’s premier bio research & innovation hub with a portfolio spread over the entire life sciences spectrum. Its AMR programmes are designed to identify and accelerate commercialization of innovations. Its analytical and technology platforms are accessible to researchers in a service mode. Further, C-CAMP’s marquee start-ups such as Bugworks have risen to international prominence with an exciting pipeline of next generation broad-spectrum antimicrobials. C-CAMP is also a member of the CARB-X Global Accelerator Network, a league of 10 top organizations combating AMR across USA and Europe.

IHMA has a diverse library of clinically relevant phenotypically and genotypically characterized bacterial and fungal isolates that can be used to assist with profiling of anti-infective agents during development.

Dr Darcie Carpenter, director, global business development, IHMA welcoming the MoU said “The IHMA Team is very excited about collaborating with C-CAMP. This MoU with C-CAMP will help provide additional support to Indian innovators to create the next generation antibiotics to fight AMR.”

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
Avians_2025
chemexpoindia
ana-Lab-India_25
Copyright © 2024 Saffron Media Pvt. Ltd | twitter
 
linkedin
 
 
linkedin
 
instagram